15-SORRENTO-Therapeutics-Logo-FINAL.png
Sorrento Announces Updated Positive Results of Phase 1b Study of COVI-MSC™ for Treatment of ICU COVID-19 Patients
25 mars 2021 15h58 HE | Sorrento Therapeutics, Inc.
All nine patients with acute respiratory failure due to COVID-19 discharged from hospital within days after 3rd COVI-MSC infusionPreparations are ongoing for initiating Phase 2 placebo-controlled...
15-SORRENTO-Therapeutics-Logo-FINAL.png
Sorrento Announces Positive Preliminary Results of Phase 1b Study of COVI-MSC™ for Treatment of ICU COVID-19 Patients
26 janv. 2021 19h09 HE | Sorrento Therapeutics, Inc.
First three patients discharged from Hospital ICU within 8 days from initial IV administration  No infusion-related adverse events noted for any patient treated to date  SAN DIEGO, Jan. 26, 2021 ...